August 22, 2022
John M. Pederson, Kathryn Cowie, Averi Barrett et al.
BACKGROUND Psilocybin is a naturally occurring psychedelic that induces feelings of euphoria and spiritual awakening when administered in doses of approximately 20-30 mg/70 kg. In the last decade, there has been renewed interest in using psilocybin for major depressive disorder (MDD). OBJECTIVE This individual patient data meta-analysis will investigate the efficacy and safety of psilocybin for...
Zeitschrift für Phytotherapie
August 1, 2022
Carhart-Harris R, Giribaldi B, Nutt DJ et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402–1411. doi:10.1056/ NEJMoa2032994
Journal of Palliative Medicine
August 1, 2022
William E Rosa, Zachary Sager, Megan Miller et al.
49 citations
Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence supports PAT as a novel therapeutic approach that provides safe and effective treatment for people suffering from a variety of diagnoses, including treatment-resistant depression, substance use disorder, and post-traumatic stress disorder. Within...
International Journal of Bipolar Disorders
July 5, 2022
Oliver G. Bosch, Simon Halm, Erich Seifritz
35 citations
Abstract This is a narrative review about the role of classic and two atypical psychedelics in the treatment of unipolar and bipolar depression. Since the 1990s, psychedelics experience a renaissance in biomedical research. The so-called classic psychedelics include lysergic acid diethylamide (LSD), psilocybin, mescaline and ayahuasca. Characteristic effects like alterations in sensory...
Journal of Psychedelic Studies
June 9, 2022
Annie M. Mccartney, Hugh McGovern, Alexander de Foe
8 citations
Abstract Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state...
Medicine, health care, and philosophy
June 1, 2022
Riccardo Miceli Mcmillan, Christopher Jordens
15 citations
Psychedelic-assisted Psychotherapy (PAP) combines the use of psychedelic compounds, such as psilocybin, with psychotherapy. PAP has shown some promise as a novel treatment for Major Depressive Disorder (MDD), and empirical research suggests that its efficacy turns on the altered states induced by psychedelic compounds. In this paper we draw on the literature of phenomenology to explain the...
Journal of Clinical Oncology
June 1, 2022
Manish Agrawal, Paul Thambi, Sarah Shnayder
3 citations
12097 Background: More than 17 million people in the U.S. live with cancer and up to 25% of them have major depression. Depression leads to lower treatment adherence, reduced quality of life, and higher rates of mortality in cancer. Yet, interventions used to treat depression in patients with cancer have limited success. Prior trials using psilocybin to treat anxiety and depression associated...
Journal of Psychopharmacology
May 30, 2022
Chaitra Jairaj, James J Rucker
13 citations
Background: Postpartum depression (PPD) is a major public health concern and has, at its core, a sense of maternal ‘disconnection’ – from the self, the infant, and the support system. While PPD bears similarities with MDD, there is increasing evidence for its distinct nature, especially with the unique aspect of the mother-infant relationship. Current treatment modalities for PPD, largely based...
Cureus
May 27, 2022
Robert Sotille, Herpreet Singh, Anne Weisman et al.
2 citations
Current medications have not been effective in reducing the prevalence of mental illness worldwide. The prevalence of illnesses such as treatment-resistant depression has increased despite the widespread use of a broad set of psychopharmaceuticals. Transcranial magnetic stimulation and ketamine therapy are making great strides in improving treatment-resistant depression outcomes but they have...
Psychiatric News
May 23, 2022
Richard Karel
Back to table of contents Previous article Next article Clinical & ResearchFull AccessPsilocybin-Assisted Therapy Found to Improve Depression, Offer Other BenefitsRichard KarelRichard KarelSearch for more papers by this authorPublished Online:23 May 2022https://doi.org/10.1176/appi.pn.2022.06.6.30AbstractA small study involving 24 participants found that psilocybin therapy was safe and...